Reducing HbA1c in T2D: Efficacy of Immune-Modulator Anti-Inflammatory Treatments

Share this content:
Study participants received either diacerein or placebo treatment for 48 weeks.
Study participants received either diacerein or placebo treatment for 48 weeks.

HealthDay News — An immune-modulator anti-inflammatory drug, diacerein, reduces the mean HbA1c levels in patients with type 2 diabetes (T2D), according to a study published online in Diabetes Care.

Claudia R.L. Cardoso, PhD, from the Universidade Federal do Rio de Janeiro, and colleagues conducted a randomized trial involving 84 patients with HbA1c between 7.5% and 9.5%. Eighty-four participants were randomized to 48-week treatment with placebo (41 patients) or diacerein 100 mg/day (43 patients).

The researchers found that, compared with placebo, diacerein reduced HbA1c by 0.35% in the intention-to-treat analysis and by 0.41% in the per-protocol analysis. At the 24th week of treatment, the peak of effect occurred (-0.61% and -0.78%, respectively); the effect attenuated toward nonsignificant differences at the 48th week. Diacerein had no significant effect in other efficacy and safety measures. Sixty-five percent of patients receiving diacerein had diarrhea, and treatment was interrupted in 16%. Insulin dosage was reduced in 7 patients in the diacerein group, while dosage was increased for 10 patients in the placebo group.

"The drug was well tolerated and may be indicated as adjunct treatment in patients with type 2 diabetes, particularly in those with osteoarthritis," the authors write.

Reference

Cardoso CRL, Leite NC, Carlos FO, Loureiro AA, Viegas BB, Salles GF. Efficacy and safety of diacerein in patients with inadequately controlled type 2 diabetes: a randomized controlled trial [published online August 17, 2017]. Diabetes Care. doi:10.2337/dc17-0374

You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters